Core Viewpoint - New Oxygen Technology is undergoing a significant strategic transformation amid a slowdown in online traffic and increasing regulation in the medical beauty industry, with a notable shift from online services to offline light medical beauty chain operations [1][2]. Financial Performance - In Q2, New Oxygen reported total revenue of 379 million yuan, a year-on-year decline of 7.0% [3]. - The company experienced a net loss of 36 million yuan in Q2, compared to a profit of 18.9 million yuan in the same period last year [4]. - Revenue from information and appointment services, a core business, fell by 35.6% to 135 million yuan, indicating intensified competition and regulatory pressures [3][4]. Business Transition - New Oxygen's offline light medical beauty chain business saw a remarkable growth of 426.1% in revenue, reaching 144 million yuan, becoming the largest revenue source for the company [1][6]. - The company plans to expand its "New Oxygen Youth Clinic" brand across China, aiming for a thousand-store scale in 8 to 10 years [6][7]. Operational Strategy - The management emphasizes a self-operated model for new stores, which allows for controlled capital expenditure and shorter payback periods, supported by a cash reserve of 999 million yuan [8]. - A franchise model is also being considered, with plans to pilot 2 to 3 franchise stores later this year [9]. Market Outlook - The rapid growth of the light medical beauty market is attracting more participants, leading to increased competition, which poses ongoing challenges for New Oxygen [9].

Core Insights - The company is undergoing a significant transformation, facing structural challenges in the traditional internet medical beauty platform, as evidenced by a 7% year-over-year decline in total revenue to 379 million yuan and a net loss of 36 million yuan compared to a profit of 18.9 million yuan in the same period last year [1][3]. Revenue Performance - Total revenue for the first half of the year was 676 million yuan, down 6.9% year-over-year, with net losses widening to 67.95 million yuan from just 60,000 yuan in the same period last year [3]. - Revenue from information and appointment services, the company's core business, fell by 35.6% to 135 million yuan from 210 million yuan year-over-year, highlighting intense competition in the online medical beauty information service market [4]. - Revenue from medical product sales and maintenance services decreased by 28.1% to 76 million yuan from 106 million yuan year-over-year, reflecting a significant drop in order volume for medical beauty products [4]. Business Segment Analysis - The total transaction volume facilitated by the platform was 304 million yuan, down from 428 million yuan in the same period last year, indicating challenges in the traditional business sector [4]. - The offline chain business has seen explosive growth, with medical treatment service revenue increasing by 426.1% to 144 million yuan, becoming the largest revenue source for the company [5]. - As of June 30, the company operated 29 light medical beauty chain stores in major cities, with 25 stores achieving positive monthly operational cash flow, indicating a promising profitability outlook [5]. Strategic Initiatives - The company plans to expand the number of medical beauty centers to 50 by the end of 2025, with a long-term goal of reaching 1,000 stores within 8 to 10 years, reflecting management's confidence in the offline business strategy [5]. - The company is innovating its operational model by reducing drug and device distribution costs through centralized procurement and self-built product lines, achieving store efficiency rates 3 to 5 times higher than similar institutions [6].

Core Viewpoint - The launch of SILKROSE's new product marks a significant milestone in the medical aesthetics industry, showcasing innovative light medical beauty technology and the first domestically produced PEG cross-linked sodium hyaluronate gel with complete independent intellectual property rights [1][8]. Group 1: Product Innovation - The PEG cross-linking technology is highlighted as a key innovation, creating a richer three-dimensional network that enhances product elasticity and prevents displacement and deformation [2][4]. - The safety design of the product is noteworthy, as the PEG fragments released after hyaluronic acid degradation can be completely metabolized in the body, eliminating accumulation risks [4]. - Clinical data indicates that the product's effect can last over 9 months, achieving a balance between "natural dynamism" and "long-lasting safety" [4]. Group 2: Expert Insights - Experts at the event emphasized the broad application prospects of PEG cross-linking technology in the medical aesthetics field, with a focus on technological innovation and product quality [5]. - A roundtable discussion among renowned medical aesthetics experts addressed the comprehensive evaluation system for new technologies and materials in facial rejuvenation treatments, indicating a shift from "incremental competition" to "quality competition" in the light medical beauty market [7]. Group 3: Strategic Partnerships - A strategic cooperation agreement was signed between JianKai Technology and China Resources Shanghai, aiming to leverage channel advantages for accelerated market coverage of the new product [8]. - Since its listing in 2020, JianKai Technology has contributed to the development and production of various PEG-modified drugs and medical devices, both domestically and internationally [8]. Group 4: Market Outlook - With the official launch of SILKROSE and subsequent market promotion, JianKai Technology aims to empower medical beauty institutions through material innovation, fostering a win-win ecosystem for enterprises, institutions, and consumers [10].

Core Viewpoint - New Oxygen Technology is undergoing a significant strategic transformation amid a slowdown in online traffic and increasing regulation in the medical beauty industry, with a notable shift from online services to offline light medical beauty chain operations [1][2]. Financial Performance - In Q2, New Oxygen reported total revenue of 379 million yuan, a year-on-year decline of 7.0% [3]. - The company experienced a net loss of 36 million yuan in Q2, compared to a profit of 18.9 million yuan in the same period last year [4]. - Revenue from information and appointment services, a core business, fell by 35.6% to 135 million yuan, indicating intensified competition and regulatory pressures [3][4]. Business Transformation - New Oxygen's offline light medical beauty chain business saw a dramatic increase, with revenue soaring by 426.1% to 144 million yuan, becoming the largest revenue source for the company [1][5]. - The company aims to expand its "New Oxygen Youth Clinic" brand across major cities, with plans to increase the number of medical centers to 50 by the end of 2025 [6][7]. Market Position and Strategy - The management emphasizes the importance of standardization and product innovation to maintain market leadership in the light medical beauty sector [5]. - New Oxygen plans to adopt a mixed model of self-operated and franchised stores, with pilot franchise stores expected to launch in Q4 [7]. Future Outlook - The company has set a long-term goal of achieving a thousand-store scale within 8 to 10 years, reflecting confidence in the growth potential of the light medical beauty market [6][7]. - Despite the positive developments, New Oxygen faces challenges from increasing competition as more players enter the light medical beauty market [8].

（文章来源：证券日报） 证券日报网讯爱美客8月15日在互动平台回答投资者提问时表示，公司在引进海外先进技术、开展海外 临床试验与注册、拓展海外市场等方面持续探索。收购韩国REGEN公司不仅将国外先进的产品、技术 与服务引入国内，同时可以利用REGEN公司丰富的市场经验和渠道实现产品出海。公司通过收购项目 获取产品和技术，缩短自主研发的时间成本，加速产品迭代升级，从而不断提升公司的核心竞争力。 ...

Group 1 - The company, Aimeike (300896), emphasizes a steady development philosophy in its operations [1] - The company aims to enhance market competitiveness through improved product performance, differentiation, service quality, and brand influence [1] - The long-term strategy is believed to be more beneficial for the company's sustainable development [1]

Market Overview - US stock index futures showed mixed performance, with Dow futures up by 0.59% and S&P 500 futures up by 0.12%, while Nasdaq futures declined by 0.05% [1] - European indices had varied results, with Germany's DAX up by 0.09%, UK's FTSE 100 down by 0.11%, France's CAC40 up by 0.58%, and the Euro Stoxx 50 up by 0.27% [2][3] - WTI crude oil prices fell by 0.53% to $63.62 per barrel, while Brent crude oil prices decreased by 0.39% to $66.58 per barrel [3][4] Geopolitical Events - A significant meeting is scheduled between US President Trump and Russian President Putin in Alaska, focusing on the Russia-Ukraine conflict and peace prospects, marking their first in-person meeting in four years [5] Federal Reserve Insights - Federal Reserve Chairman Powell is set to speak at the Jackson Hole conference on August 22, with market expectations leaning towards a potential 25 basis point rate cut due to inflation and a slowing job market [6] - Bank of America warns that if the Fed signals a dovish stance at Jackson Hole, US stocks may face a "buy the rumor, sell the news" scenario, indicating potential market corrections [7] Hedge Fund Activity - Hedge funds have significantly increased their holdings in technology stocks during Q2, with notable purchases in Microsoft and Netflix, amidst a backdrop of market volatility due to trade policies [8] Economic Concerns - Bank of America raised concerns about the potential for the dollar to face challenges if the Fed lowers rates while inflation is rising, a scenario not seen in nearly 20 years [9] Company Performance - Tuniu (TOUR.US) reported a 15.3% year-over-year increase in Q2 revenue, with a new $10 million stock buyback plan announced [10] - New Oxygen (SY.US) experienced a 7.0% decline in Q2 revenue, attributed to a decrease in the number of medical service providers subscribing to its platform [11] - Applied Materials (AMAT.US) provided disappointing Q4 guidance, raising concerns about demand suppression due to US-China trade tensions [11] - Cloud Mi Technology (VIOT.US) expects over 1.4 billion RMB in revenue for the first half of 2025, a growth of over 70% year-over-year, driven by increased sales of home water purification devices [12]

Investment Rating - The industry investment rating is "Overweight" [8] Core Viewpoints - The report indicates that social retail sales maintained steady growth, with a year-on-year increase of 3.7% in July, supported by national subsidies [3][4] - Essential categories like grain, oil, and food showed stronger resilience, while discretionary categories such as gold and jewelry, and cosmetics saw improved performance [4] - Online retail channels continued to grow, with a 9.2% year-on-year increase in online retail sales from January to July 2025, while offline retail growth showed signs of marginal slowdown [5] Summary by Sections Social Retail Sales - The total retail sales of consumer goods from January to July 2025 reached 28,423.8 billion yuan, with July sales at 3,878 billion yuan, reflecting a year-on-year growth of 4.8% and 3.7% respectively [3] - Urban and rural retail sales increased by 4.8% and 4.7% year-on-year [3] Price Factors - The overall Consumer Price Index (CPI) remained stable, with food CPI down by 1.6% year-on-year [4] - Retail sales in various categories showed different growth rates, with essential goods like grain and oil up by 8.6% year-on-year, while discretionary items like cosmetics and jewelry saw increases of 4.5% and 8.2% respectively [4] Online vs Offline Channels - Online retail sales reached 86,835 billion yuan from January to July 2025, with physical goods online sales at 70,790 billion yuan, accounting for 24.9% of total retail sales [5] - Offline retail growth rates for supermarkets, convenience stores, and department stores showed a slight decline compared to the previous month [5] Investment Recommendations - The report suggests focusing on high-quality companies in sectors aligned with "emotional consumption," particularly in gold jewelry, offline retail, cosmetics, and medical aesthetics [6] - Specific recommendations include brands like Lao Pu Gold and Chao Hong Ji in gold jewelry, and companies like Mao Ge Ping and Pechoin in cosmetics [6]

Investment Rating - The report indicates a positive outlook for the Poly-L-Lactic Acid (PLA) industry, with a projected compound annual growth rate (CAGR) of 20.4% from 2024 to 2030, suggesting strong investment potential in this sector [46][48]. Core Insights - The PLA market in China is still in its early stages, with a market size of approximately 1 billion yuan in 2021, expected to grow to 11 billion yuan by 2024 and reach 41 billion yuan by 2030 [48]. - The industry is characterized by a competitive landscape with 9 approved products and several others in development, indicating a diverse market with both domestic and imported brands [39]. - The rise of non-surgical aesthetic procedures has positioned PLA products like the "童颜针" (Youthful Needle) favorably, as they cater to a growing consumer base seeking natural anti-aging solutions [40][45]. Summary by Sections 1. Industry Overview - The PLA industry is primarily driven by the increasing demand for non-surgical aesthetic treatments, with a significant shift in consumer preferences towards natural and long-lasting results [40][45]. - The report highlights the importance of consumer education, as many potential users still confuse PLA products with traditional fillers, which may hinder market penetration [57][61]. 2. Market Dynamics - The PLA market is expected to benefit from a growing user base, particularly among the Z generation, who are becoming the main consumers of aesthetic procedures [84]. - The report notes that the market is currently dominated by domestic brands, with a focus on competitive pricing and innovative formulations [39]. 3. Competitive Landscape - The competitive landscape includes both domestic and imported brands, with a notable presence of 9 approved PLA products, each with distinct technical features and pricing strategies [33][39]. - The report outlines the pricing range for various products, indicating a clear segmentation in the market from high-end to more affordable options [34]. 4. Consumer Insights - Consumer motivations for seeking PLA treatments include personal satisfaction and social value, with safety and effectiveness being primary concerns [62][64]. - The report emphasizes the need for improved consumer understanding of PLA products, as many potential users are not fully aware of the benefits and mechanisms of action [57][61]. 5. Future Opportunities - The report identifies several growth opportunities, including the increasing penetration of aesthetic procedures among younger consumers and the potential for product innovation through technology [86][87]. - Regulatory changes are expected to enhance product quality and safety, further driving consumer trust and market growth [51][87].

Core Viewpoint - The dispute over the exclusive agency rights for the "童颜针" (AestheFill) between *ST Suwu and the medical beauty giant Aimeike has escalated, with *ST Suwu seeking arbitration and claiming significant financial losses due to alleged breaches of contract [2][5][6]. Group 1: Company Actions and Legal Proceedings - *ST Suwu's subsidiary, Datou Medical, has filed for arbitration with the Shenzhen International Arbitration Court regarding a breach of contract by Regen, seeking to confirm its exclusive agency rights for AestheFill and claiming preliminary damages of 1.6 billion yuan [2][6]. - The arbitration request was accepted by the Shenzhen International Arbitration Court on August 7, 2025 [5]. - *ST Suwu has publicly accused Aimeike of "capital bullying" and "serious damage to business ethics" in its defense [2][8]. Group 2: Financial Context and Company Performance - *ST Suwu is facing severe financial difficulties, including risks of forced delisting due to financial fraud allegations, with a reported inflated revenue of 1.77 billion yuan from 2020 to 2023 [3][9]. - Aimeike, which acquired 85% of Regen for $190 million in March 2025, is also experiencing declining financial performance, with revenue and net profit growth rates dropping to single digits in 2024 [3][12]. - Aimeike's market capitalization has decreased from over 180 billion yuan at its peak to approximately 60 billion yuan, reflecting a loss of over 120 billion yuan [4][14]. Group 3: Market Implications and Future Outlook - The ongoing dispute over the AestheFill agency rights is critical for both companies, as AestheFill is seen as a potential growth driver for Aimeike amidst its declining performance [10][11]. - The market has reacted negatively to the news, with *ST Suwu's stock price experiencing consecutive trading halts following the announcement of the termination of its agency rights [8]. - The outcome of the arbitration and the future of the AestheFill product in the Chinese market remain uncertain, with significant implications for both companies and their stakeholders [4][15].